11 startups pitch top Houston angel investors at biannual summit

money moves

The Houston Angel Network's investors heard from growing startups in their portfolio — along with a few prospects. Getty Images

The Houston Angel Network checked in with their investors and portfolio companies at their biannual Houston Angel Summit that gathered HAN members, local investors, and startup founders for a day full of educational opportunities, pitches, and fireside chats.

The event, which took place last week at Rice University's Liu Idea Lab for Innovation and Entrepreneurship, featured 11 startups – both new and more familiar to HAN members – pitching their growing companies in hopes of catching the interest of potential investors.

BioMedical Music Solutions

Austin-based BioMedical Music Solutions has a SaaS platform that uses artificial intelligence and music to accelerate rehabilitation at a lower cost. Founder Hope Young explained her years-proven therapy can work its magic in one-third of the time and one-tenth of the cost of traditional physical therapy sessions.

Optelos

Houston-based Optelos has a patented SaaS solution that can transform physical asset images, videos, and documents into what's known as a "Digital Inspection Twin" that can enabling knowledge workers utilizing our unified data management, reality modeling, and in-process artificial intelligence solution, to digitally visualize, analyze and manage their entire asset base.

Pocket Naloxone

Maryland-based Pocket Naloxone is attempting to solve the opioid crisis. The company has a portfolio of over-the-counter drug overdose reversal agents, including a naloxone OTC product.

AI Driller

Houston-based AI Driller is using mathematic algorithms to apply automation on rigs for drilling. The startup can also offer its clients real-time data and cuts out the opportunity for human error.

Cavu Biotherapies

Houston pet immunotherapy company, Cavu Biotherapies, has seen a tremendous amount of growth and is now a treatment partner at 43 clinic providers in 18 states and Canada. Founder Colleen O'Connor says she's seen a near 600 percent growth in revenue over the past year and treated 38 dog cancer patients in that timeframe.

CorInnova

Another Houston company, CorInnova, has created a device from a soft, flexible material that can be easily inserted through a 1-inch incision, and then be used for increase blood pumping in the heart by 50 percent.

Hive Genie

Houston-based Hive Genie is using technology to help beekeepers optimize their pollination operations and monitor hive operations remotely. Gone are the days, Hive Genie hopes, that beekeepers need to suit up to track and maintain their colonies physically.

Siera AI

Austin-based Siera AI is using its AI-enabled cloud IoT platform for logistics solutions and safety improvements in warehouse settings. A goal of the company's, according to its website, is to free humans from these types of dull, dangerous, dirty tasks.

Skycom

The sky's not even the limit for Austin-based Skycom and its airship technology that supplies low-cost cell towers in orbit. The technology can bring down the cost of mobile service providers and allow for growth into new markets.

Tevido

Another Austin company, Tevido uses a pigment cell graft process to use patients' own skin cells to restore normal skin color for patients with vitiligo and pale scars.

Tot Squad

Los Angeles-based Tot Squad emerged as a service-focused company for baby-related tasks and now has emerged as a digital marketplace connecting service providers online to parents and to-be parents for needs like stroller cleaning or carseat installation.

With the Texas Medical Center in their backyard, these Houston biotech companies are creating breakthrough technologies. Getty Images

5 Houston biotech companies taking health care to new levels

The future is now

Houston is the home of the largest medical center in the world, so it comes as no surprise that the Bayou City is also home to breakthrough technologies. Here are five Houston companies developing some of this biotech advancements.

Moleculin Biotech Inc.

Houston-based Moleculin has three different oncology technologies currently in trials. Getty Images

Immunotherapy and personalized medicine get all the headlines lately, but in the fight against cancer, a natural compound created by bees could beat them in winning one battle.

In 2007, chairman and CEO Walter Klemp founded Moleculin Biotech Inc. as a private company. The former CPA had found success in life sciences with a company that sold devices for the treatment of acne. That introduction into the field of medical technology pushed him toward more profound issues than spotty skin.

"Coincidentally, the inventor of that technology had a brother who was a neuro-oncologist at MD Anderson," Klemp recalls.

The since-deceased Dr. Charles Conrad slowly lured Klemp into what he calls the "cancer ecosphere" of MD Anderson. In 2016, the company went public. And it looks like sooner rather than later, it could make major inroads against some of the toughest cancers to beat. Read the full story here.

Cavu Biotherapies

Dr. Colleen O'Connor has adapted immunotherapy treatments to be used in dogs. Courtesy of CAVU Biotherapies

Breakthrough biotech doesn't have to just be for humans. More than three years after its founding, Houston-based veterinary biotech company CAVU Biotherapies' had its first cancer patient: a black Labrador in Pennsylvania diagnosed with B-cell lymphoma.

Dr. Colleen O'Connor, CEO and founder of CAVU Biotherapies, established the company in July 2015 with a goal to help pets live longer post-cancer diagnoses. O'Connor, who earned a PhD in toxicology with a specialty in immunology, has more than a decade of hands-on experience researching cancer treatments.

"Our goal is to scale up and be able to increase our dogs' qualities of life with us," O'Connor said. "We want to keep families intact longer and we want to be able to modernize cancer care for our animals." Read the full story here.

Innovative Biochips

iBiochips, led by founder Lidong Qin, was awarded a $1.5 million grant in September to help develop a new technology that delivers data about the cell's genetic makeup and reports abnormalities. Courtesy of Lidong Qin

Innovative Biochips, a Houston-based biotechnology company, is one step closer to commercializing technology that the company hopes will provide an opportunity for researchers to detect diseases earlier.

The company was founded three years ago by Dr. Lidong Qin, a professor at the Houston Methodist Research Institute's department of nanomedicine. He launched iBiochips as an independent faculty startup that licensed technology from Houston Methodist. Qin says he wanted to engineer and manufacture devices that focus on revolutionizing single-cell isolation and genetic analysis. Read the full story here.

Celltex

Celltex's stem cell technology has received positive results from its multiple sclerosis, Parkinson's, and rheumatoid arthritis patients. Courtesy of Celltex

A Houston stem cell company is making strides in regenerative medicine. Celltex's treatment has been proved effective with its patients. Eighty-three percent of multiple sclerosis patients have reported improvement of symptoms specific to their disease, as have 73 percent of Parkinson's sufferers. But the staggering fact is that 100 percent of 58 respondents with rheumatoid arthritis say they have benefited.

David Eller, chairman, co-founder and CEO of the company, also recently announced the company's expansion to Saudi Arabia. Read the full story here.

Ridgeline Therapeutics

Houston-based Ridgeline Therapeutics isn't going to allow you beat aging, but someday it may well help you to live without muscle loss or diabetes. Getty Images

Stan Watowich pictures a world where elderly people have the same healthy muscles they had at a younger age. Watowich is CEO of Ridgeline Therapeutics, a spin-off company of the University of Texas Medical Branch in Galveston where he is an associate professor of biochemistry and molecular biology, and he wants to make it clear that he is not going to cure aging.

"You and I are still going to get old," he says. "But we have our hopes that as we get old our muscles will stay healthy."

He's talking about the drug candidate, RLT-72484. It has been shown to reactivate muscle stem cells and regenerate skeletal muscle in aged laboratory mice. Read the full story here.


Concession food to your seat? Sign InnovationMap readers up. Courtesy of sEATz

5 top trending innovation stories in Houston this week

What you're reading

Editor's note: Not entirely surprisingly, this week's views were skewed heavily toward an app that allows stadium food delivery right to your seat, wine-picking technology, a slideshow of a growing coworking space, and more.

Houston startup is making stadium food a whole new ballgame

A new app, sEATz, is the UberEats of stadium food. You order right from your phone in your seat. Getty Images

Marshall Law's wife, Melissa, surprised him and his two sons with tickets to see the Astros play at home in the 2017 World Series against the Los Angeles Dodgers, but a rush to get to the game and a packed stadium lead to him waiting in a long concessions line in the second inning.

Law watched on a TV screen next to the food counter as the fourth pitch from Yu Darvish to Yuli Gurriel hit two rows past the Laws' seats, bouncing back toward where they were supposed to be sitting. Law couldn't shake the feeling of missing out on the homer. Why couldn't someone have brought them the food, he thought. He'd have paid $50 — maybe more — to not miss that moment.

"Everything gets delivered these days. Any kind of food to your groceries, all right to you. Why isn't someone doing this?" Law says he was thought as he walked out of the game. Read the full story here.

Photos: West Houston coworking space 50 percent leased ahead of early 2019 opening

The Cannon's 120,000-square-foot space is on track to open March 1. Courtesy of The Cannon

Everything's bigger in Texas, and Houston will soon have a coworking space to reflect that. The Cannon is on track to open its West Houston 120,000-square-foot, 32-acre coworking and entrepreneurship campus by March 1.

"We're going to have, as far as I know, the biggest coworking space in the world," says Lawson Gow, founder and CEO of The Cannon. "It's a really Houston-sized solution to the problem of the challenge we set out to face." Read the full story here.

3 Houston health tech innovators to know this week

Armed with their doctorate degrees and startups, these three STEM biotech innovators are going places. Courtesy photos

Whether it's for dogs or dating, Houston is prime for innovative leaders in health science startups, and there are three in particular you need to know going into a new week. From a DNA-based dating app creator and a researcher curing cancer in dogs to cutting-edge biotech leader, here are the Houston innovators to know. Doctorate degrees and startup companies in hand, each of these entrepreneurs is going places. Read the full story here.

Houston company aims to equally equip female workers

SeeHerWork launched its line of female-gear in September. Courtesy of SeeHerWork

When Jane Henry was working on her home right after Hurricane Harvey — her house got three feet of mud in it — she went to throw a board into the dumpster, and her glove went with it.

Henry says the industry standard is to recommend small and extra-small sizes for women's workwear, but as a ladies large in athletic gloves, Henry still had a good inch or so of glove at her fingertips in her workwear gloves.

"I went upstairs to my sewing room, and I ripped that glove apart and I resewed it to fit my hand," Henry says. Read the full story here.

Houston entrepreneur makes a splash with wine-selecting technology

Houston-based VineSleuth created a custom algorithm to match you with new wines based on wines you've had in the past. Courtesy of VineSleuth

Amy Gross wants to find you the perfect wine. In fact, she wants it so much, she built her company, VineSleuth, around the concept that technology and machine learning could find the best wine to match individual palates.

VineSleuth's custom algorithm is backed by research from sensory scientists at Cornell University, and relies on both data collection and machine learning to determine specific wines that will match an individual customer's tastes. Flavor profiles from thousands of wines are incorporated into her database, and none of those are based on the typical wine scores you'll see in magazines or reviews of wines. Read the full story here.


Armed with their doctorate degrees and startups, these three STEM biotech innovators are going places. Courtesy photos

3 Houston heath tech innovators to know this week

Who's Who

Whether it's for dogs or dating, Houston is prime for innovative leaders in health science startups, and there are three in particular you need to know going into a new week. From a DNA-based dating app creator and a researcher curing cancer in dogs to cutting-edge biotech leader, here are the Houston innovators to know. Doctorate degrees and startup companies in hand, each of these entrepreneurs is going places.

Brittany Barreto, co-founder and CEO of Pheramor

Courtesy of Pheramor

Brittany Barreto was studying genetics in college, and her professor was talking about how there are 11 genes in DNA that can determine physical compatibility with others. She had the idea right then and there in the classroom to make a DNA-based dating app. Almost 10 years later, she's done it, with Pheramor.

The Houston startup has launched nationwide and is in the midst of another capital campaign. Barreto is also looking to expand her team to account for the growth and success.

Lidong Qin, founder of Innovative Biochips

Courtesy of Lidong Qin

Lidong Qin spends his days as a professor at the Houston Methodist Research Institute's department of nanomedicine, but three years ago, he expanded his resume. He launched his biotech startup, Innovative Biochips, as an independent faculty startup that licensed technology from Houston Methodist.

Qin says it can be difficult to launch a biotech startup in Houston, since the industry requires hefty initial funds to open a facility, get patents and hire a team of researchers. Now, iBiochips is armed with private investments and a $1.5 million grant from the National Institutes of Health's Small Business Technology Transfer program to continue researching and developing early disease detection technologies.

Colleen O'Connor, founder of CAVU Biotherapies 

CAVU Colleen O'Connor

Courtesy of CAVU Biotherapies

Losing a pet is awful, and for so many people, pets are full-blown family members. When Colleen O'Connor lost her furry family members to cancer, she knew she had to do something about it. Cancer treatment in humans had evolved to include immunotherapy, and O'Connor thought man's best friend deserved an upgrade from the 1980s practices veterinarians use.

She created Houston-based CAVU Biotherapies, and, in September, the first treatment was administered to a black lab named Franklin. O'Connor is focused on expanding her treatment and its access to pups so that no pet owner has to prematurely say goodbye to good boys and girls.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Texas tops ranking of best state for investors in new report

by the numbers

Texas ranks third on a new list of the best states for investors and startups.

Investment platform BrokerChooser weighed five factors to come up with its ranking:

  • 2024 Google search volume for terms related to investing
  • Number of investors
  • Number of businesses receiving investments in 2024
  • Total amount of capital invested in businesses in 2024
  • Percentage change in amount of investment from 2019 to 2024

Based on those figures, provided mostly by Crunchbase, Texas sits at No. 3 on the list, behind No. 1 California and No. 2 New York.

Especially noteworthy for Texas is its investment total for 2024: more than $164.5 billion. From 2019 to 2024, the state saw a 440 percent jump in business investments, according to BrokerChooser. The same percentages are 204 percent for California and 396 percent for New York.

“There is definitely development and diversification in the American investment landscape, with impressive growth in areas that used to fly under the radar,” says Adam Nasli, head analyst at BrokerChooser.

According to Crunchbase, funding for Texas startups is off to a strong start in 2025. In the first three months of this year, venture capital investors poured nearly $2.9 billion into Lone Star State companies, Crunchbase data shows. Crunchbase attributes that healthy dollar amount to “enthusiasm around cybersecurity, defense tech, robotics, and de-extincting mammoths.”

During the first quarter of this year, roughly two-thirds of VC funding in Texas went to just five companies, says Crunchbase. Those companies are Austin-based Apptronik, Austin-based Colossal Biosciences, Dallas-based Island, Austin-based NinjaOne, and Austin-based Saronic.

Autonomous truck company rolls out driverless Houston-Dallas route

up and running

Houston is helping drive the evolution of self-driving freight trucks.

In October, Aurora opened a more than 90,000-square-foot terminal at a Fallbrook Drive logistics hub in northwest Houston to support the launch of its first “lane” for driverless trucks—a Houston-to-Dallas route on the Interstate 45 corridor. Aurora opened its Dallas-area terminal in April and the company began regular driverless customer deliveries between the two Texas cities on April 27.

Close to half of all truck freight in Texas moves along I-45 between Houston and Dallas.

“Now, we are the first company to successfully and safely operate a commercial driverless trucking service on public roads. Riding in the back seat for our inaugural trip was an honor of a lifetime – the Aurora Driver performed perfectly and it’s a moment I’ll never forget,” Chris Urmson, CEO and co-founder of Pittsburgh-based Aurora, said in a news release.

Aurora produces software that controls autonomous vehicles and is known for its flagship product, the Aurora Driver. The software is installed in Volvo and Paccar trucks, the latter of which includes brands like Kenworth and Peterbilt.

Aurora previously hauled more than 75 loads per week under the supervision of vehicle operators from Houston to Dallas and Fort Worth to El Paso for customers in its pilot project, including FedEx, Uber Freight and Werner. To date, it has completed over 1,200 miles without a driver.

The company launched its new Houston to Dallas route with customers Uber Freight and Hirschbach Motor Lines, which ran supervised commercial pilots with Aurora.

“Transforming an old school industry like trucking is never easy, but we can’t ignore the safety and efficiency benefits this technology can deliver. Autonomous trucks aren’t just going to help grow our business – they’re also going to give our drivers better lives by handling the lengthier and less desirable routes,” Richard Stocking, CEO of Hirschbach Motor Lines, added in the statement.

The company plans to expand its service to El Paso and Phoenix by the end of 2025.

“These new, autonomous semis on the I-45 corridor will efficiently move products, create jobs, and help make our roadways safer,” Gov. Greg Abbott added in the release. “Texas offers businesses the freedom to succeed, and the Aurora Driver will further spur economic growth and job creation in Texas. Together through innovation, we will build a stronger, more prosperous Texas for generations.”

In July, Aurora said it raised $820 million in capital to fuel its growth—growth that’s being accompanied by scrutiny.

In light of recent controversies surrounding self-driving vehicles, the International Brotherhood of Teamsters, whose union members include over-the-road truckers, recently sent a letter to Lt. Gov. Dan Patrick calling for a ban on autonomous vehicles in Texas.

“The Teamsters believe that a human operator is needed in every vehicle—and that goes beyond partisan politics,” the letter states. “State legislators have a solemn duty in this matter to keep dangerous autonomous vehicles off our streets and keep Texans safe. Autonomous vehicles are not ready for prime time, and we urge you to act before someone in our community gets killed.”

Houston cell therapy company launches second-phase clinical trial

fighting cancer

A Houston cell therapy company has dosed its first patient in a Phase 2 clinical trial. March Biosciences is testing the efficacy of MB-105, a CD5-targeted CAR-T cell therapy for patients with relapsed or refractory CD5-positive T-cell lymphoma.

Last year, InnovationMap reported that March Biosciences had closed its series A with a $28.4 million raise. Now, the company, co-founded by Sarah Hein, Max Mamonkin and Malcolm Brenner, is ready to enroll a total of 46 patients in its study of people with difficult-to-treat cancer.

The trial will be conducted at cancer centers around the United States, but the first dose took place locally, at The University of Texas MD Anderson Cancer Center. Dr. Swaminathan P. Iyer, a professor in the department of lymphoma/myeloma at MD Anderson, is leading the trial.

“This represents a significant milestone in advancing MB-105 as a potential treatment option for patients with T-cell lymphoma who currently face extremely limited therapeutic choices,” Hein, who serves as CEO, says. “CAR-T therapies have revolutionized the treatment of B-cell lymphomas and leukemias but have not successfully addressed the rarer T-cell lymphomas and leukemias. We are optimistic that this larger trial will further validate MB-105's potential to address the critical unmet needs of these patients and look forward to reporting our first clinical readouts.”

The Phase 1 trial showed promise for MB-105 in terms of both safety and efficacy. That means that potentially concerning side effects, including neurological events and cytokine release above grade 3, were not observed. Those results were published last year, noting lasting remissions.

In January 2025, MB-105 won an orphan drug designation from the FDA. That results in seven years of market exclusivity if the drug is approved, as well as development incentives along the way.

The trial is enrolling its single-arm, two-stage study on ClinicalTrials.gov. For patients with stubborn blood cancers, the drug is providing new hope.

View All Listings